Newer Therapeutic Targets in Head and Neck Cancers

Condition(s) studied

Investigational drug(s) / intervention(s)

Next generation Sequencing: Next generation sequencing for 161 genes

Study summary

Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes:

1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA);
2. cell-cycle control (e.g., CDKN2A and CCND1);
3. cellular differentiation (e.g., NOTCH1); and
4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways.

Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known

Eligibility

Primary outcome measure(s)

• Over all survival — 10 years
  Survival time from the diagnosis to death
• Relapse free survival — 10 years
  survival time from diagnosis to recurrence or metastasis

Trial sites (1)

More Banaras Hindu University trials in India

Other trials for the same condition